Plus Therapeutics (PSTV.US): The 2024 Q1 financial report achieved revenue of US$1.677 million, with a previous value of US$506,000 and an expected value of US$1.69 million; earnings per share were -0.75 dollars, previous value was -2.07 US dollars, and e
Plus Therapeutics (PSTV.US): The 2024 Q1 financial report achieved revenue of US$1.677 million, with a previous value of US$506,000 and an expected value of US$1.69 million; earnings per share were -0.75 dollars, previous value was -2.07 US dollars, and expected value was -1.09 US dollars.
Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(
Plus Therapeutics Inc. Q1 Loss Decreases, Beats Estimates
Plus Therapeutics 1Q Loss/Shr 75c >PSTV
Plus Therapeutics 1Q Loss/Shr 75c >PSTV
Press Release: Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recom
Plus Therapeutics | 10-Q: Quarterly report
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)
Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The FORESEE Trial, Met Its Primary Endpoint Of Clinical Utility
CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda Company summarized topline data from the FORESEE cli
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data From the FORESEE Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the CNSide cerebrospinal fluid (CSF) testing assets.
Press Release: Plus Therapeutics Announces Private Placement Financing of up to $18 Million
Plus Therapeutics Announces Private Placement Financing of up to $18 Million $6.5 million in upfront gross proceeds with the potential to receive up to an additional $11.5 million in potential warran
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The
Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Press Release: Plus Therapeutics Receives $3 Million Award Recommendation From the United States Department of Defense
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic p
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Plus Therapeutics Faces Nasdaq Delisting Over Equity Shortfall
Plus Therapeutics CEO's Insightful Presentation Now Available
No Data